Ethan joined BioNews in 2022 after two decades in the health information and publishing world, where he launched, grew, and eventually sold Vertical Health to Remedy Health Media. After several years in business development at Remedy, he came to BioNews to focus on elevating content and community support for health conditions that deserve greater visibility. His connection to rare disease is also personal, with a close family member living with a rare condition.
A graduate of Cornell University, Ethan lives in Ithaca, NY, with his wife, Rachel, a mental health therapist, and their three boys — Rylan, Liam, and Eli. Beyond his work in healthcare, he founded the Youth Entrepreneurship Market (www.YEMithaca.com), helping young people build entrepreneurial skills and bring their ideas to life. He was recently honored as Ithaca’s Hometown Hero for his work with local youth and his service on multiple mission-driven boards and committees.

Kim Moran is the Senior Vice President and Head of U.S. Rare Diseases at UCB, where she leads the company’s rare disease commercial organization and sets the strategic direction for its U.S. portfolio. Her work spans operations, regulatory, clinical, technology, and marketing, and she is known for building high-performing teams grounded in innovation and a deep understanding of patient needs.
In 2023–2024, Kim led cross-functional teams through the FDA approvals and U.S. launches of two rare disease assets that represent major growth drivers for UCB. Over her 17-year career with the company, she has played a key role in its evolution — helping UCB move closer to patients, identify unmet needs, and deliver impactful solutions, including digital pathways and data-driven programs.
Kim’s insights-led approach has opened new markets, advanced operational efficiency, and accelerated UCB’s digital business transformation. Her previous roles include Head of Insights to Impact, Head of U.S. Neurology Strategy, and Head of Epilepsy Portfolio Strategy, where she translated patient and caregiver insights into programs that strengthened UCB’s leadership in epilepsy. Earlier, she led lifecycle and medical affairs planning for key neurology and movement disorder products.
Her career began in rare disease, working in myasthenia gravis — a space that shaped her belief that understanding patients deeply comes with a responsibility to be bold on their behalf. Kim holds an Executive Global MBA from INSEAD, a Ph.D. in Neuroscience and Physiology from New York University, and a BS in Biochemistry and Molecular Biology from Penn State University. She sits on the board of Nile AI, an epilepsy care management platform, and has been recognized across the industry, including honors from the Healthcare Businesswomen’s Association and Medical Marketing + Media.

Dr. Marcella Debidda, PhD is a healthcare innovation leader with over 15 years of experience advancing research and care strategies shaped by the lived experience of patients and caregivers across organizations including Harvard Clinical Research Institute, Science 37, and monARC Bionetworks and Stanford Medicine X.
She is widely recognized for developing scalable approaches to incorporate patient and caregiver expertise into research design, clinical development, and policy decision-making.
Dr. Debidda has led initiatives in patient-powered trial design, recruitment and engagement strategies, and sustainable rare-disease community development across more than 50 conditions.
At Bionews she leads the Clinical and the Patient Insights divisions.
Her career spans collaborations with pharmaceutical and biotechnology companies, advocacy organizations, and academic partners, integrating behavioral science, qualitative research, and community engagement to address unmet needs in rare and underserved populations.